Palbociclib showed antiproliferative activity in early-stage breast cancer

April 19, 2016

The molecularly targeted therapeutic palbociclib (Ibrance), which is used to treat advanced breast cancer, was effective in slowing the multiplication of cancer cells in patients diagnosed with early-stage breast cancer who received no prior therapy, according to data from a phase II clinical trial presented here at the AACR Annual Meeting 2016, April 16-20.

"The use of targeted therapies has been increasing in the last few years. It is crucial to determine that these drugs do hold activity against tumor cells," said the study's lead author, Monica Arnedos, MD, an assistant professor at Gustave Roussy Cancer Campus in Villejuif, France. "In the case of , no predictive biomarkers have been identified to date, and there are still no data about its potential efficacy in the early setting."

Palbociclib, an inhibitor of cyclin-dependent kinases (CDK) 4 and 6, was approved by the U.S. Food and Drug Administration (FDA) in February 2015 for use in combination with the anti-estrogen therapeutic letrozole for treating postmenopausal women with a specific subtype of : estrogen receptor-positive, HER2-negative, .

In this clinical trial, Arnedos and colleagues sought to determine whether short-term preoperative palbociclib treatment was associated with decreased cancer cell proliferation and other biomarker changes in the tumors of with different subtypes of early-stage breast cancer.

This randomized study included 100 women who had been diagnosed with early-stage breast cancer. Seventy-four received 125 mg of oral palbociclib daily for 14 days leading up to breast cancer surgery. The 26 patients in the control arm received no treatment. Overall, 93 percent of the tumors were hormone receptor-positive (HR+)/HER2-negative (HER2-) and 8 percent were HER2-positive. Tissue samples were extracted at baseline and at surgery.

The study found that 58 percent of patients who had received palbociclib had an antiproliferative response in their tumors, compared with 10 percent of those in the control group.

Specifically, the researchers found that the protein Ki67, which is a marker of cell proliferation, decreased in the tumors of patients treated with palbociclib. The change was most significant in patients with HR+/HER2- breast cancer. In that group, 72 percent of patients showed decreased Ki67, compared with 5 percent of the patients in the control group. Arnedos noted that no Ki67 response was observed in women with HER2-positive tumors or . However, she noted that a limitation of the study is that there weren't enough patients with HR-negative breast cancer, which made it difficult to interpret the findings for that group.

Arnedos plans to discuss the effect of palbociclib on several other biomarkers at the meeting, including PIK3CA, an oncogene that is commonly mutated in certain subtypes of breast cancer.

Although further research will be necessary to confirm the findings of this study, Arnedos said the results were promising for a new body of patients.

"Palbociclib works in untreated , and the magnitude of this activity was higher than expected," Arnedos said.

Explore further: Drug combination slows breast cancer spread

Related Stories

Drug combination slows breast cancer spread

March 2, 2016
A combination of two drugs delays progression of advanced, aggressive breast cancer by an average of nine months - working in all subsets of the most common type of breast cancer.

Asian women with endocrine-resistant breast cancer benefit from combination therapy

December 18, 2015
Data collected in Japanese and Korean patients included in the global PALOMA3 trial provides evidence that combining palbociclib with fulvestrant is an effective strategy to overcome endocrine resistance in women with hormone ...

New targeted therapy shows promise against breast cancer

May 30, 2015
Pfizer's new targeted drug, palbociclib, has been shown to halt the progression of the most common form of advanced breast cancer in women, researchers said Saturday.

Palbociclib shows promising results in patients with hormone receptor-positive metastatic breast cancer

April 7, 2014
The drug palbociclib, an inhibitor of cyclin-dependent kinases (CDK) 4 and 6, significantly improved progression-free survival when administered as a first-line treatment in patients with hormone receptor-positive, metastatic ...

Evidence show new drug combination may improve outcomes for women with advanced breast cancer

April 18, 2016
Results from the I-SPY 2 trial show that giving patients with HER2-positive invasive breast cancer a combination of the drugs trastuzumab emtansine (T-DM1) and pertuzumab before surgery was more beneficial than the combination ...

Single dose of trastuzumab kick starts immune response in certain breast cancers

February 29, 2016
A tumor's immune response to a single dose of the HER2 inhibitor trastuzumab predicted which patients with HER2-positive breast cancer would respond to the drug on a more long-term basis, according to the results of a study ...

Recommended for you

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.